List of Excipients in Branded Drug ETHYOL

Ethyol Excipient Strategy and Commercial Opportunities for Amifostine

Last updated: August 5, 2026

Ethyol is the injectable amifostine product used as a cytoprotective agent during radiation therapy and selected chemotherapy regimens. Its commercial opportunity is limited by niche demand, administration burden, and the age of the active-ingredient estate. The strongest opportunities are therefore formulation-led: improved reconstitution, reduced preparation time, better chemical stability, lower dosing friction, and hospital-ready presentations.

The core excipient platform is simple. Ethyol is a sterile lyophilized powder containing amifostine and mannitol, reconstituted before intravenous administration. The principal development challenge is maintaining amifostine stability while preserving a rapid, practical clinical workflow.[1]

What excipients are used in Ethyol?

Ethyol is supplied as a sterile lyophilized powder for injection. The marketed vial contains amifostine with mannitol as the principal non-active excipient. The product is reconstituted with Sterile Water for Injection before administration.[1]

Product attribute	Ethyol profile
Active ingredient	Amifostine
Dosage form	Sterile lyophilized powder for injection
Primary excipient	Mannitol
Reconstitution medium	Sterile Water for Injection
Administration	Intravenous infusion
Key formulation issue	Aqueous instability and rapid preparation requirements
Clinical setting	Radiation oncology and selected chemotherapy protocols
Commercial channel	Institutional and specialty hospital use

Mannitol has several formulation functions. It can provide bulking during lyophilization, improve cake structure, contribute to tonicity after reconstitution, and support a relatively simple excipient profile. Its use also avoids preservatives and minimizes the number of formulation variables in a parenteral product.

The current formulation is commercially functional but not optimized for convenience. The need for reconstitution, infusion timing, blood-pressure monitoring, and protocol-specific administration creates barriers that a new presentation could address.

How does amifostine stability affect excipient selection?

Amifostine is a phosphorylated thiol prodrug that is converted in vivo to the active free thiol WR-1065. The active thiol chemistry creates formulation sensitivity, particularly in aqueous systems. Hydrolysis, oxidation, pH exposure, oxygen ingress, and trace-metal catalysis are central risks for liquid formulations.

Formulation risks

A reformulation program would need to control:

• Water activity during storage
• Oxygen exposure in the vial or container
• Residual moisture after lyophilization
• Reconstitution pH
• Oxidative degradation
• Metal-catalyzed degradation
• Container-closure permeability
• Hold time after reconstitution
• Compatibility with infusion materials

The existing lyophilized format addresses the most important stability problem by removing water during storage. A liquid ready-to-use product would face a materially higher stability burden and could require a combination of pH control, oxygen reduction, chelation, antioxidant protection, and higher-barrier packaging.

Candidate excipient classes

Excipient class	Potential function	Commercial value	Principal risk
Mannitol	Bulking agent and lyophilized cake former	High	Limited differentiation from current product
Trehalose or sucrose	Lyoprotectant and glass-forming stabilizer	Medium to high	May alter cake structure and reconstitution
Histidine or phosphate buffer	pH control	Medium	Buffer strength may affect degradation
Citrate buffer	pH control and possible metal interaction	Medium	Compatibility and pH-dependent stability
EDTA or related chelator	Control of trace-metal catalysis	Medium	Regulatory and parenteral tolerability assessment
Methionine or other antioxidant	Oxidation control	Medium	May complicate impurity profile
Arginine	Solubility and protein-like stabilization function	Low to medium	Limited rationale for a small-molecule thiophosphate
Poloxamer or surfactant	Interface protection in liquid or reconstituted systems	Low to medium	May be unnecessary and add injectable-excipient complexity

A rational development sequence would begin with mannitol-based lyophilized systems, then evaluate trehalose or sucrose as alternative stabilizing bulking agents. Buffer selection should be driven by degradation mapping rather than by conventional parenteral formulation practice.

Chelators and antioxidants could improve chemical stability, but they also create additional safety, compatibility, and regulatory work. A simple excipient platform is likely to have a stronger hospital and generic-market proposition than a complex formulation with marginal stability gains.

What formulation patents could protect an improved Ethyol product?

The strongest protectable subject matter would likely be a new dosage form, stability profile, administration method, or container system rather than the basic amifostine molecule.

Potential formulation patent categories

A new amifostine product could seek patent protection for:

1. A stable liquid amifostine formulation with defined pH and impurity limits.
2. A lyophilized composition containing amifostine, mannitol, and a second stabilizer.
3. A low-oxygen or oxygen-scavenging container-closure system.
4. A ready-to-use infusion bag or dual-chamber device.
5. A formulation with an extended post-reconstitution hold time.
6. A formulation that reduces infusion-related hypotension through modified concentration or administration volume.
7. A subcutaneous, intramuscular, oral, or depot delivery system.
8. A specific method for treating radiation-induced xerostomia or chemotherapy-related toxicities.
9. A manufacturing process that improves residual moisture, reconstitution time, or impurity control.
10. A combination product pairing amifostine with an antiemetic, blood-pressure management protocol, or radiation regimen.

A formulation patent would need more than the substitution of one conventional excipient for another. The most defensible claims would link composition variables to measurable performance, such as improved stability, reduced reconstitution time, reduced degradation products, or a longer permitted hold period.

When does amifostine lose exclusivity?

The core amifostine exclusivity period is historical. Ethyol was approved in the United States decades ago, and ordinary small-molecule regulatory exclusivity has expired. Any original composition or use patents associated with early development would also generally be expected to have expired or be near the end of their useful commercial life.

Exclusivity category	Ethyol position
New chemical entity exclusivity	Expired
Original composition patents	Historical and generally expired
Orange Book patent strategy	No durable core-molecule position should be assumed
Formulation exclusivity	Depends on any later, separately patented product
Method-of-use exclusivity	Indication-specific and historically limited
Biosimilar exclusivity	Not applicable
Generic pathway	Abbreviated New Drug Application pathway is the relevant route for injectable amifostine

The commercial protection available to a new entrant would therefore come from a new formulation, device, delivery route, manufacturing process, or clinical-use patent. Regulatory exclusivity could arise only from a qualifying new clinical or formulation development program, not from the legacy Ethyol product itself.

What is the Orange Book status of Ethyol?

Ethyol is a small-molecule injectable drug, so the relevant regulatory framework is an NDA and potential ANDA competition rather than a biologic license application and biosimilar pathway. The FDA Orange Book is the governing source for listed patents and therapeutic-equivalence information.[2]

The strategic implication is direct: a new amifostine product should not rely on legacy Ethyol brand recognition or historical patent protection. A differentiated formulation would need to establish its own regulatory and intellectual-property position.

Patent listings could be relevant if a later NDA contains an active formulation or method-of-use patent. In practice, the more important barrier may be CMC execution. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable requirements for a sterile injectable product. A novel delivery system could instead require a 505(b)(2) application, especially if it changes route, dosage form, concentration, or clinical use.

What generic entry risks exist for Ethyol?

Generic entry risk is high for the conventional lyophilized injectable format because:

• The active ingredient is old.
• The dosage form is established.
• The excipient system is relatively simple.
• The product has no biologic comparability barrier.
• Institutional buyers are accustomed to injectable procurement.
• Clinical differentiation is limited when the generic matches the approved use and administration profile.

A generic applicant could compete through lower acquisition cost, reliable supply, and standard vial presentations. The principal barriers are sterile manufacturing, product stability, limited market size, and the need to maintain supply for a specialized oncology market.

Paragraph IV challenges

A Paragraph IV challenge would be most relevant only if a live Orange Book-listed patent covered a later Ethyol formulation or method of use. A challenge to an expired core patent would not create meaningful litigation leverage. A new formulation sponsor could seek the opposite position: build a patent estate around a differentiated formulation and use Paragraph IV litigation to delay follow-on entry.

The litigation risk for a new formulation would depend on whether the patent claims:

• The entire composition or only narrow excipient ranges
• A clinically meaningful performance outcome
• A specific impurity or stability threshold
• A defined container or device
• A method of use that is difficult to carve out
• A manufacturing step that generic competitors cannot easily avoid

Which companies are challenging or competing with Ethyol?

The competitive set is broader than amifostine manufacturers. Ethyol competes with other approaches to reducing radiation or chemotherapy toxicity.

Competitive category	Examples	Relevance to Ethyol
Amifostine generics	Generic injectable manufacturers	Direct price competition
Radiotherapy techniques	IMRT, VMAT, image-guided radiation	Reduce exposure to normal tissue
Xerostomia drugs	Pilocarpine and related therapies	Address symptoms rather than protect tissue during treatment
Chemoprotective agents	Sodium thiosulfate and protocol-specific agents	Compete in selected toxicity-prevention indications
Supportive care	Hydration, antiemetics, nutritional and oral-care protocols	Reduce treatment burden without amifostine
Delivery innovation	Ready-to-use infusion products and closed transfer systems	Potentially improve adoption and procurement

Sodium thiosulfate has particular competitive relevance in selected pediatric chemotherapy settings, although it is not a direct substitute across all Ethyol indications. The competitive question is usually whether amifostine changes clinical outcomes enough to justify its preparation burden, blood-pressure monitoring, adverse effects, and acquisition cost.

What formulation opportunities could create a commercial advantage?

Ready-to-use liquid presentation

A ready-to-use infusion bag could eliminate vial reconstitution and reduce pharmacy preparation time. Its main technical barrier is long-term aqueous stability. The product would need a credible shelf life, low impurity formation, and compatibility with standard infusion systems.

A dual-chamber container may offer a more achievable path. Amifostine could remain in a dry compartment until administration, while diluent is stored separately. This design could preserve dry-state stability while reducing preparation steps.

Faster-reconstituting lyophilized vial

A lower-risk development strategy would retain the lyophilized format but improve:

• Reconstitution time
• Cake integrity
• Vial labeling
• Dose selection
• Transfer-device compatibility
• Post-reconstitution stability
• Reduced residual moisture

This approach could support a 505(b)(2) or product-improvement strategy, depending on the development claims and regulatory pathway.

Lower-volume or higher-concentration product

Reducing infusion volume could improve convenience, but higher concentration may affect solubility, local tolerability, osmolality, and administration requirements. A concentration change must be tied to a clear clinical or operational benefit.

Alternative route of administration

Oral and subcutaneous delivery could expand use, but these are high-risk programs. Oral amifostine would need to overcome absorption, enzymatic conversion, gastrointestinal tolerability, and exposure variability. Subcutaneous or intramuscular delivery would require new local-tolerance and pharmacokinetic studies.

Combination product

A product that integrates amifostine with a supportive-care protocol could improve adherence, but combination claims may face limited patent breadth. The strongest commercial use case would be a hospital protocol package supported by clinical evidence rather than an excipient-only product.

How strong is the Ethyol patent estate?

The legacy patent estate is weak as a platform for long-term exclusivity because amifostine is an established small molecule with an old approval history. The estate could still have value if a sponsor controls later patents covering a specific formulation, device, or treatment method.

Patent asset type	Expected strategic strength
Original amifostine composition	Low due to age
Basic injectable formulation	Low to medium
Narrow excipient ranges	Medium if linked to unexpected stability data
Ready-to-use liquid formulation	Medium to high if long-term stability is demonstrated
Dual-chamber device	Medium, subject to design-around risk
Manufacturing process	Medium if impurity control is difficult to replicate
New route of administration	Potentially high, but clinically expensive
Method-of-use patent	Variable and vulnerable to carve-outs

Patent strength would be highest where the formulation produces a measurable, clinically relevant improvement that competitors cannot achieve through routine optimization.

What licensing deals could support an Ethyol reformulation?

A commercial program could use several licensing structures:

• License-in of a lyophilization platform
• Co-development with a sterile injectable manufacturer
• Device license for a dual-chamber or ready-to-use system
• Hospital-network partnership for workflow and health-economic studies
• Regional license to a specialty oncology distributor
• Manufacturing and supply agreement with a contract development and manufacturing organization

The most practical structure would combine formulation ownership with outsourced sterile manufacturing. Ethyol demand is likely too specialized to justify a large internal manufacturing footprint without a broader oncology injectable portfolio.

What is the FDA regulatory pathway for a new amifostine product?

A conventional generic injectable would generally use an ANDA if it can demonstrate equivalence to the reference product. A materially different formulation, delivery system, concentration, route, or indication could require a 505(b)(2) application.[3]

Product concept	Likely pathway
Same active, strength, route, and dosage form	ANDA
New excipient system with clinical differentiation	505(b)(2) may apply
Ready-to-use liquid with new stability profile	505(b)(2) likely
Dual-chamber device	505(b)(2) or combination-product review
New route of administration	505(b)(2) with new clinical data
New therapeutic indication	505(b)(2) or supplemental NDA strategy
New biologic-like formulation	Biosimilar pathway not applicable

FDA review would focus on sterility assurance, particulate matter, impurities, container closure, reconstitution, stability, compatibility, and clinical bridging. For an injectable reformulation, excipient safety and administration performance are central development issues rather than secondary formulation details.

What revenue exposure and commercial opportunity does Ethyol present?

Ethyol is a niche hospital product rather than a broad primary-care franchise. Revenue exposure is concentrated in oncology centers and treatment protocols where the clinical value of cytoprotection is accepted and reimbursement supports use.

The commercial opportunity is strongest in three areas:

1. A lower-cost generic with dependable supply.
2. A hospital-efficiency product that reduces pharmacy preparation and waste.
3. A differentiated formulation supported by new clinical utility.

The market is unlikely to support a premium product based only on a cosmetic excipient change. A successful product would need to reduce total treatment burden, improve stability, simplify administration, or expand use into a clinically important setting.

Key Takeaways

• Ethyol is an amifostine lyophilized injectable that uses mannitol as its principal excipient.
• The main technical problem is amifostine instability in aqueous systems.
• The strongest opportunities are ready-to-use, dual-chamber, fast-reconstituting, or lower-waste presentations.
• Core-molecule and original Ethyol exclusivity are historical; new value must come from formulation, device, manufacturing, or method-of-use patents.
• Generic entry risk is high for the conventional vial format.
• An ANDA is relevant for a closely equivalent generic; a 505(b)(2) application is more likely for a clinically differentiated formulation.
• The most defensible formulation patents would connect excipient selection to unexpected stability, impurity, reconstitution, or administration results.
• Biosimilar competition is not relevant because amifostine is a small molecule.
• Commercial success depends more on hospital workflow, supply reliability, and clinical utility than on brand positioning.

FAQs About Ethyol Excipient and Reformulation Opportunities

Can mannitol be replaced in an amifostine formulation?

Yes. Trehalose, sucrose, or other lyophilization excipients could be evaluated, but replacement would need to demonstrate better stability, cake quality, reconstitution, or clinical handling.

Could amifostine be developed as a ready-to-use infusion?

Yes, but the liquid product would face substantially greater stability and packaging requirements than the existing dry powder. A dual-chamber presentation may provide a lower-risk alternative.

Is Ethyol eligible for biosimilar competition?

No. Amifostine is a small-molecule drug. Competition would arise through generic or 505(b)(2) pathways, not through biosimilar approval.

What is the most valuable patent claim for a new amifostine product?

A claim covering a stable composition with defined excipient ranges and a demonstrated improvement in shelf life, impurity control, reconstitution, or administration would generally be more valuable than a routine excipient substitution claim.

Could a new amifostine formulation obtain market exclusivity?

Potentially. A qualifying new formulation, delivery system, indication, or clinical-use change could support regulatory exclusivity, subject to the applicable FDA pathway and statutory requirements.

References

1. U.S. Food and Drug Administration. (n.d.). Ethyol (amifostine) for injection prescribing information. DailyMed, National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. FDA Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA Center for Drug Evaluation and Research.

5. National Cancer Institute. (n.d.). Amifostine. NCI Drug Dictionary.